Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of 17.55 billion. The enterprise value is 22.54 billion.

Market Cap	17.55B
Enterprise Value	22.54B

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Sep 27, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.87%
Shares Change (QoQ)	-0.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.79B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.37, with an EV/FCF ratio of 27.78.

EV / Earnings	-61.72
EV / Sales	1.78
EV / EBITDA	8.37
EV / EBIT	16.86
EV / FCF	27.78

Financial Position

The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.61.

Current Ratio	1.04
Quick Ratio	0.73
Debt / Equity	0.61
Debt / EBITDA	2.29
Debt / FCF	7.17
Interest Coverage	11.16

Financial Efficiency

Return on equity (ROE) is -3.83% and return on invested capital (ROIC) is 5.24%.

Return on Equity (ROE)	-3.83%
Return on Assets (ROA)	3.67%
Return on Invested Capital (ROIC)	5.24%
Return on Capital Employed (ROCE)	8.72%
Revenue Per Employee	805,144
Profits Per Employee	-24,757
Employee Count	14,754
Asset Turnover	0.55
Inventory Turnover	1.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.73% in the last 52 weeks. The beta is 0.16, so Astellas Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	-8.73%
50-Day Moving Average	9.63
200-Day Moving Average	10.49
Relative Strength Index (RSI)	76.32
Average Volume (20 Days)	2,645

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of 11.88 billion and -365.27 million in losses. Loss per share was -0.20.

Revenue	11.88B
Gross Profit	9.68B
Operating Income	1.28B
Pretax Income	-495.99M
Net Income	-365.27M
EBITDA	2.55B
EBIT	1.28B
Loss Per Share	-0.20

Full Income Statement

Balance Sheet

The company has 1.14 billion in cash and 5.82 billion in debt, giving a net cash position of -4.68 billion.

Cash & Cash Equivalents	1.14B
Total Debt	5.82B
Net Cash	-4.68B
Net Cash Per Share	n/a
Equity (Book Value)	9.50B
Book Value Per Share	5.31
Working Capital	326.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.05 billion and capital expenditures -240.64 million, giving a free cash flow of 811.49 million.

Operating Cash Flow	1.05B
Capital Expenditures	-240.64M
Free Cash Flow	811.49M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.50%, with operating and profit margins of 10.73% and -3.07%.

Gross Margin	81.50%
Operating Margin	10.73%
Pretax Margin	-4.18%
Profit Margin	-3.07%
EBITDA Margin	21.45%
EBIT Margin	10.73%
FCF Margin	6.83%

Dividends & Yields

This stock pays an annual dividend of 0.26, which amounts to a dividend yield of 2.56%.

Dividend Per Share	0.26
Dividend Yield	2.56%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	0.87%
Shareholder Yield	3.43%
Earnings Yield	-2.08%
FCF Yield	4.62%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Astellas Pharma has an Altman Z-Score of 1.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.92
Piotroski F-Score	n/a